Background. Two adolescents with acute B-cell leukemia (Burkitt leukemia) had acute severe neurotoxicity after treatment with intrathecal (IT) cytosine arabinoside (AraC) at a dose of 50 mg/day for three consecutive days. A 16-year-old boy had a rapidly ascending myelopathy and encephalopathy 20 ho
Seizures following intrathecal cytosine arabinoside in young children with acute lymphoblastic leukemia
β Scribed by O. B. Eden; W. Goldie; T. Wood; E. Etcubanas
- Publisher
- John Wiley and Sons
- Year
- 1978
- Tongue
- English
- Weight
- 680 KB
- Volume
- 42
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The importance of the cellular pharmacokinetics of cytarabine triphosphate (ara-CTP) with regard to therapeutic efficacy is well established. In vitro and in vivo monitoring of pharmacokinetic parameters of leukemic blast cells were initiated in order to contribute to the pharmacological basis of op
Courses of cytosine arabinoside followed by L-asparaginase were administered for 4 days each to 17 children with previously treated acute lymphatic leukemia, at 14to 27-day intervals. Complete or partial remission occurred in 81% of patients after the third or fourth course of therapy. Rlaintenance
## Abstract Three groups of children with acute lymphoblastic leukemia (ALL) were treated with intermittent cyclophosphamide, vincristine, cytosine arabinoside, and prednisone (COAP). Group A (no prior relapse) and Group B (prior singleβagent relapse) received COAP after 12 months on another chemot
Problem. Therapy of children with relapsed acute lymphoblastic leukemia (ALL) not achieving a second remission (CR2) after an initial reinduction attempt is problematic. Methods. 52 children with ALL in first relapse received high-dose cytosine arabinoside and L-asparaginase (HDAraC/L-Asp) after fa